0.108  0 (0%)		01-23 16:00
Open: 0.1156 High: 0.116 Volume: 31,125,310		Pre. Close: 0.108 Low: 0.0925 Market Cap: 6(M)

Short term
Mid term
Targets	6-month :	0.02	1-year :	0.03
Resists	First :	0.02	Second :	0.03
Pivot price	0.01
Supports	First :	0.01	Second :	0
MAs	MA(5) :	0.01	MA(20) :	0.01
	MA(100) :	0.15	MA(250) :	6.23
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	18.9	D(3) :	17.1
RSI	RSI(14): 27
52-week	High :	13.85	Low :	0.01

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ TCDA ] has closed above bottom band by 49.4%. Bollinger Bands are 99.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 85 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	0.02 - 0.02	0.02 - 0.02
Low:	0.01 - 0.01	0.01 - 0.01
Close:	0.01 - 0.01	0.01 - 0.01

Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

Mon, 14 Nov 2022
Tricida Announces Third Quarter 2022 Financial Results - Business Wire

Wed, 02 Nov 2022
Tricida Provides Strategic Update - Business Wire

Mon, 24 Oct 2022
Tricida Reports Topline Results from the VALOR-CKD Phase 3 Trial of Veverimer - Business Wire

Mon, 24 Oct 2022
Tricida Collapses 95%, Vaxcyte Skyrockets as Drug Trials Diverge - Bloomberg

Fri, 21 Oct 2022
Latham Advises on Tricida's US$125 Million Debt Facility - Latham & Watkins LLP

Wed, 19 Oct 2022
Tricida Announces $125 Million Debt Facility with Hercules Capital - Business Wire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	55 (M)
Shares Float	51 (M)
Held by Insiders	8 (%)
Held by Institutions	64.7 (%)
Shares Short	10,530 (K)
Shares Short P.Month	14,000 (K)

EPS	-5.3
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	2.17
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-60.2 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-2.25
Qtrly Earnings Growth	0 %
Operating Cash Flow	-109 (M)
Levered Free Cash Flow	-66 (M)

PE Ratio	-0.01
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	-0.01

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.